Table 3. Treatment and outcomes.
Treatment and outcomes | Total (134) | ICU (n = 45) | Non-ICU (89) | p value |
Complications* | ||||
ARDS | 13 (9.7%) | 13 (28.9%) | 0 | < .001 |
AKI | 8 (6%) | 8 (17.8%) | 0 | < .001 |
Extrarenal epuration | 8 (6%) | 8 (17.8%) | 0 | < .001 |
Arrythmia | 3 (2.2%) | 3 (6.6%) | 0 | .029 |
Pneumothorax | 2 (1.5%) | 2 (4.4%) | 0 | .094 |
Thromboembolic events | 4 (2.9%) | 4 (8.8%) | 0 | .012 |
Septic shock | 1 (0.01%) | 1 (2.2%) | 0 | .303 |
Death | 14 (10.4%) | 14 (31.1%) | 0 | < .001 |
Causes of death* | ||||
ARDS + AKI | 8 (5.9%) | 8 (17.8%) | 0 | < .001 |
ARDS alone | 4 (3%) | 4 (8.9%) | 0 | .012 |
Septic shock | 1 (0.7%) | 1 (2.2%) | 0 | .303 |
Decompensated cirrhosis | 1 (0.7%) | 1 (2.2%) | 0 | .198 |
Treatments* | ||||
Hydroxychloroquine | 127 (95%) | 43 (95.5%) | 84 (96.6%) | 1.000 |
Azithromycin | 127 (95%) | 43 (95%) | 84 (94.4%) | 1.000 |
Lopinavir + ritonavir | 11 (8.2%) | 11 (24.4%) | 0 | .001 |
Tocilizumab | 5 (3.7%) | 5 (11.1%) | 0 | .004 |
Cephalosporin third generation | 24 (17.9%) | 22 (48.9%) | 2 (2.2%) | < .001 |
Quinolones | 21 (15.7%) | 20 (44.4%) | 1 (1.1%) | < .001 |
Aminosides | 9 (6.7%) | 9 (20%) | 0 | < .001 |
Carbapenem | 8 (6%) | 8 (17.8%) | 0 | < .001 |
Corticosteroids | 14 (10.4%) | 14 (31.1%) | 0 | < .001 |
Low molecular weight heparin | 111 (82%) | 43 (95.6%) | 68 (76.4%) | .005 |
Catecholamines | 13 (9.7%) | 13 (28.9%) | 0 | < .001 |
Non-rebreather mask | 23 (17.2%) | 23 (51.1%) | 0 | < .001 |
Noninvasive ventilation | 8 (5.9%) | 8 (17.8%) | 0 | < .001 |
Invasive mechanical ventilation | 14 (10.4%) | 14 (31.1%) | 0 | < .001 |